Studying ocrelizumab effects in relapsing multiple sclerosis in two racial groups
Observes ocrelizumab-treated adults with relapsing multiple sclerosis using brain and eye scans.
Plain-language title generated from the registry record
Registry title: Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
Key facts
- Where
- Detroit, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT04458688, who can take part
Where in United States
- Wayne State UniversityDetroit, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Wayne State University
- Trial code
- NCT04458688
- Record updated
- 6 June 2022
- Original description
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..Read full original descriptionShow less
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis: a Novel, Advanced Multimodal MRI and Optical Coherence Tomography-Angiography (OCTA) Study
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and optical coherence tomography angiography (OCT-A)..
Inclusion: Patients who have chosen to start ocrelizumab and for whom ocrelizumab is determined to be the most appropriate standard-of-care disease modifying therapy (DMT) by the treating neurologist; May be treatment naive, or had suboptimal response to no more than one DMT after an adequate course of treatment (defined as treatment duration of 6+ months); Age 18 to 60 years old; Ethnicity: self-identified as African American or Caucasian; Clinically definite relapsing remitting multiple sclerosis (RRMS) per 2017 revised McDonald criteria; EDSS from 0 to 6 (inclusive) at baseline visit; Able to give informed consent; Able to have MRI scans.
Exclusion: Treatment with another monoclonal antibody, including but not limited to natalizumab, alemtuzumab, daclizumab; Treatment with immunosuppressant agents, such as chemotherapeutic agents; Relapse or use of corticosteroids within 30 days prior to baseline visit; Allergy to contrast; History of kidney or liver insufficiency; History of malignancy; Failed 2 or more DMTs; Claustrophobia; Significant medical problems that the PI determines will interfere with the conduct of the study; Pregnancy.